Bioxytran Signs NDA with the University of Georgia to Evaluate Galectin Antagonists for Bird Flu Treatment in Chickens

In Vitro studies have shown promise against viruses similar to the bird flu virus

BOSTON, MASSACHUSETTS, March 19, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, announced today the signing of a Non-Disclosure Agreement (NDA) with the Board of Regents of the University System of Georgia by and on behalf of the University of Georgia. The collaboration will focus on evaluating Bioxytran’s galectin antagonist as a potential treatment for chickens infected with Bird Flu. The research will be led by Dr. Daniel Perez, a renowned expert in virology and poultry medicine, who holds multiple prestigious positions at the University of Georgia, including CVI Affiliated Faculty and Caswell Eidson Chair in Poultry Medicine.

Bioxytran’s leading drug candidate, ProLectin-M, is a novel galectin antagonist designed to combat viral infections by targeting galectins, which are proteins implicated in viral replication, inflammation, and fibrosis. In vitro studies have demonstrated its effectiveness against viruses similar to the Bird Flu virus, raising hopes for its potential application in poultry and beyond.

About Bioxytran, Inc.

Bioxytran, Inc. is at the forefront of developing complex carbohydrate-based therapeutics to address critical unmet medical needs in virology, degenerative diseases, and hypoxia. The company’s three core platform technologies—glycovirology, cancer metastasis, and oxygen delivery—underpin its innovative pipeline. In addition to ProLectin-M, Bioxytran is advancing programs for pulmonary fibrosis and stroke treatment. For more information, visit

Investor Relations

Michael Sheikh

509-991-0245

Forward-Looking Statements

This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.